The New York based biotech company announces launch of Amplifier Therapeutics to develop the clinical stage pan-AMPK activator, ATX-304 NEW YORK, March 14, 2023 /PRNewswire/ Cambrian
/PRNewswire/ Cambrian BioPharma, a multi-asset longevity biotech, today unveils its latest pipeline company, Isterian Biotech. This preclinical start-up is.
/PRNewswire/ Cambrian BioPharma, a multi-asset longevity biotech, today announced that its CEO, James Peyer, has been selected as "BioTech Company CEO of.
/PRNewswire/ Cambrian BioPharma, a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. David Nicholson,.